Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.59 |
| ▸ | CA2 | P00918 | 15/20 | 0.59 |
| ▸ | CA9 | Q16790 | 15/20 | 0.59 |
| ▸ | CA12 | O43570 | 7/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | HTR3A | P46098 | 2/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5057133 | 0.88 | CA9 (0.64) | CA1CA2CA9CA12CA14 | |
| SCHEMBL24444501 | 0.84 | CA9 (0.72) | CA1CA2CA9CA12CA14 | |
| SCHEMBL24606377 | 0.83 | CA9 (0.69) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19788249 | 0.82 | CA9 (0.67) | CA1CA2CA9CA12CA14 | |
| SCHEMBL17753778 | 0.81 | CA9 (0.66) | CA1CA2CA9CA12CA14 | |
| SCHEMBL18807599 | 0.81 | FOLH1 (0.61) | CA1CA2CA9CA12CA14 | |
| SCHEMBL20529844 | 0.81 | FOLH1 (0.61) | CA1CA2CA9CA12CA14 | |
| SCHEMBL10060089 | 0.81 | FOLH1 (0.61) | CA1CA2CA9CA12CA14 | |
| SCHEMBL31380586 | 0.81 | FOLH1 (0.61) | CA1CA2CA9CA12CA14 | |
| SCHEMBL12800346 | 0.81 | CA9 (0.70) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190144386-A1 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144386-A1 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | ITGA5, ITGB5, ITGB1 | CA1 1284/4885CA2 2330/4885CA9 1517/4885 |
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | ITGA5, ITGB5, ITGB1 | CA1 1284/4885CA2 2330/4885CA9 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.